Public Employees Retirement System of Ohio Buys Shares of 8,900 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Public Employees Retirement System of Ohio bought a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $92,000.

A number of other large investors have also recently modified their holdings of PHAT. Quantbot Technologies LP boosted its holdings in shares of Phathom Pharmaceuticals by 112.6% in the 2nd quarter. Quantbot Technologies LP now owns 5,527 shares of the company’s stock valued at $46,000 after purchasing an additional 2,927 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Phathom Pharmaceuticals by 20.1% in the 2nd quarter. Legal & General Group Plc now owns 6,328 shares of the company’s stock valued at $54,000 after purchasing an additional 1,061 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Phathom Pharmaceuticals by 2,715.2% in the 2nd quarter. Osaic Holdings Inc. now owns 4,251 shares of the company’s stock valued at $59,000 after purchasing an additional 4,100 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Phathom Pharmaceuticals by 371.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company’s stock valued at $87,000 after purchasing an additional 6,641 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Phathom Pharmaceuticals in the 2nd quarter valued at $87,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ:PHAT opened at $10.62 on Friday. The firm has a market cap of $621.06 million, a P/E ratio of -2.74 and a beta of 0.63. The company has a quick ratio of 10.22, a current ratio of 10.25 and a debt-to-equity ratio of 5.56. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $17.02. The business has a fifty day simple moving average of $8.50 and a 200 day simple moving average of $8.85.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.12. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same period in the prior year, the business earned ($1.33) earnings per share. Analysts predict that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current year.

Insider Buying and Selling

In other Phathom Pharmaceuticals news, CFO Molly Henderson sold 6,307 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $7.75, for a total transaction of $48,879.25. Following the completion of the sale, the chief financial officer now directly owns 98,698 shares in the company, valued at approximately $764,909.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Phathom Pharmaceuticals news, CFO Molly Henderson sold 6,307 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $7.75, for a total transaction of $48,879.25. Following the completion of the sale, the chief financial officer now directly owns 98,698 shares in the company, valued at approximately $764,909.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $8.10, for a total value of $29,999,994.30. Following the sale, the insider now owns 3,755,583 shares of the company’s stock, valued at $30,420,222.30. The disclosure for this sale can be found here. Insiders sold a total of 3,726,861 shares of company stock valued at $30,202,386 in the last three months. Insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, March 22nd.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.